CONTENTS

PREFACE xix
LIST OF ABBREVIATIONS xxii

UNIT I  GENERAL INTRODUCTION 1

1  Introduction to Cardiovascular Diseases 3
  1.1 Overview 3
  1.2 Definition of Cardiovascular Diseases 3
  1.3 Classification of Cardiovascular Diseases 3
    1.3.1 Classification Based on Anatomical Location 3
    1.3.2 Classification Based on the Involvement of Atherosclerosis 4
    1.3.3 Total Cardiovascular Diseases and ICD-10 Classification 4
  1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases 5
    1.4.1 NCDs and Cardiovascular Diseases: The Global Status 7
    1.4.2 The Status of Cardiovascular Diseases in the United States 7
    1.4.3 The Status of Cardiovascular Diseases in China 8
  1.5 Risk Factors of Cardiovascular Diseases 9
    1.5.1 Classification of Cardiovascular Disease Risk Factors 9
    1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact 9
  1.6 Prevention and Control of Cardiovascular Diseases 10
    1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level 10
    1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases 12
    1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health 12
    1.6.4 US DHSS “Million Hearts” Initiative 14
  1.7 Cardiovascular Risk Prediction and Evidence-Based Treatments 15
    1.7.1 Cardiovascular Risk Prediction 15
    1.7.2 Evidence-Based Treatments 18
  1.8 Summary of Chapter Key Points 18
  1.9 Self-Assessment Questions 18

References 19
2 Introduction to Principles of Pharmacology  21
  2.1 Overview  21
  2.2 Definitions and History  21
      2.2.1 What Is Pharmacology?  21
      2.2.2 Definitions of Related Terms  22
      2.2.3 A Brief History of Pharmacology  22
  2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology  24
      2.3.1 Drug Names, Sources, Preparations, and Administration  24
      2.3.2 Pharmacokinetics  28
      2.3.3 Pharmacodynamics  28
      2.3.4 Drug Toxicity  28
      2.3.5 Pharmacogenetics and Pharmacogenomics  29
  2.4 Principles of Drug Discovery, Development, and Regulation  31
      2.4.1 Definitions  31
      2.4.2 The Paradigm of Drug Creation and Survival  31
      2.4.3 The FDA Drug Review and Approval Process  32
  2.5 Pharmacology Subspecialties  32
  2.6 Introduction to Cardiovascular Pharmacology  32
      2.6.1 Definition and Scope  32
      2.6.2 New Developments and Challenges  32
      2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases  34
      2.6.4 Polypill for the Management of Cardiovascular Diseases  35
      2.6.5 Protein Therapeutics of Cardiovascular Diseases  35
      2.6.6 Gene Therapy of Cardiovascular Diseases  35
      2.6.7 Stem Cell Therapy of Cardiovascular Diseases  36
  2.7 Summary of Chapter Key Points  38
  2.8 Self-Assessment Questions  39
References  40

UNIT II  DYSLIPIDEMIAS  43

3 Overview of Dyslipidemias and Drug Therapy  45
  3.1 Introduction  45
  3.2 Lipoprotein Metabolism  45
      3.2.1 Definition, Structure, and Classification of Lipoproteins  45
      3.2.2 Metabolic Pathways of Lipoproteins and Drug Therapy  47
  3.3 Dyslipidemias and Genetic Lipoprotein Disorders  51
      3.3.1 Classification and Molecular Etiologies  51
      3.3.2 The Four Types of Dyslipidemias and Their Underlying Genetic Lipoprotein Disorders  51
  3.4 Mechanistically Based Drug Therapy of Dyslipidemias  51
  3.5 Summary of Chapter Key Points  53
  3.6 Self-Assessment Questions  54
References  54

4 Drugs for Dyslipidemias  56
  4.1 Overview  56
  4.2 Statins  56
      4.2.1 General Introduction to Drug Class  56
      4.2.2 Chemistry and Pharmacokinetics  57
      4.2.3 Molecular Mechanisms and Pharmacological Effects  58
      4.2.4 Clinical Uses  61
CONTENTS

4.10 Emerging Therapeutic Modalities for Dyslipidemias 88
   4.10.1 Emerging Therapeutic Strategies Targeting LDL 88
   4.10.2 Novel Therapeutic Strategies Targeting HDL 90
   4.10.3 Summary of Emerging Drugs 93

4.11 Summary of Chapter Key Points 93

4.12 Self-Assessment Questions 93

References 95

5 Management of Dyslipidemias: Principles and Guidelines 99
   5.1 Overview 99
   5.2 General Principles of the Management of Dyslipidemias 99
      5.2.1 Defining Dyslipidemias in the Context of Disease Management 99
      5.2.2 Understanding Laboratory Lipid Profiles 100
      5.2.3 Cardiovascular Risk Assessment 101
      5.2.4 Treatment Goals 101
      5.2.5 General Approaches to Management: Lifestyle Modifications
         and Drug Therapies 101
      5.2.6 Management in Specific Clinical Settings 101
      5.2.7 Treatment Monitoring and Adherence 102
   5.3 Current Evidence-Based Guidelines on the Management of Dyslipidemias 102
      5.3.1 Defining Clinical Guidelines in the Context of Dyslipidemia Management 102
      5.3.2 Classification of Evidence-Based Guideline Recommendations and Strength of Evidence 102
      5.3.3 Current Guidelines on the Management of Dyslipidemias 103
      5.3.4 Comparison and Contrast of Current Lipid Guidelines 108
   5.4 Summary of Chapter Key Points 113
   5.5 Self-Assessment Questions 113

References 114

UNIT III HYPERTENSION AND MULTITASKING
CARDIOVASCULAR DRUGS 117

6 Overview of Hypertension and Drug Therapy 119
   6.1 Introduction 119
   6.2 Definitions, Classifications, and Epidemiology of Hypertension 119
      6.2.1 Definitions and Classifications 119
      6.2.2 Epidemiology and Health Impact of Hypertension 120
   6.3 Pathophysiology of Hypertension 121
      6.3.1 Physiology of Blood Pressure Regulation 121
      6.3.2 Molecular Pathophysiology of Hypertension Development 122
   6.4 Mechanistically Based Drug Therapy of Hypertension: An Overview 123
      6.4.1 Historical Overview 123
      6.4.2 Mechanistic Overview 123
   6.5 Summary of Chapter Key Points 123
   6.6 Self-Assessment Questions 125

References 125

7 Diuretics 127
   7.1 Overview 127
   7.2 Volume Regulation and Drug Targeting 127
      7.2.1 Renal Physiology and Volume Regulation 127
      7.2.2 Drug Class and Drug Targeting 128
   7.3 Thiazide and Thiazide-Type Diuretics 129
      7.3.1 General Introduction to Drug Class 129
      7.3.2 Chemistry and Pharmacokinetics 129
CONTENTS

7.3.3 Molecular Mechanisms and Pharmacological Effects 130
7.3.4 Clinical Uses 131
7.3.5 Therapeutic Dosages in Cardiovascular Applications 132
7.3.6 Adverse Effects and Drug Interactions 133
7.3.7 Summary of Thiazide and Thiazide-Type Diuretics 134
7.4 Loop Diuretics 134
7.4.1 General Introduction to Drug Class 134
7.4.2 Chemistry and Pharmacokinetics 134
7.4.3 Molecular Mechanisms and Pharmacological Effects 134
7.4.4 Clinical Uses 136
7.4.5 Therapeutic Dosages in Heart Failure Treatment 137
7.4.6 Adverse Effects and Drug Interactions 137
7.4.7 Summary of Loop Diuretics 137
7.5 Potassium-Sparing Diuretics 138
7.5.1 General Introduction to Drug Class 138
7.5.2 Chemistry and Pharmacokinetics 138
7.5.3 Molecular Mechanisms and Pharmacological Effects 139
7.5.4 Clinical Uses 140
7.5.5 Therapeutic Dosages 141
7.5.6 Adverse Effects and Drug Interactions 141
7.6 Other Diuretics 142
7.7 Summary of Chapter Key Points 143
7.8 Self-Assessment Questions 143
References 144

8 Sympatholytics 147
8.1 Overview 147
8.2 Sympathetic Nervous System and Drug Targeting 147
8.2.1 Basic Divisions of the Nervous System 147
8.2.2 Sympathetic Nervous System and Cardiovascular Diseases 148
8.2.3 Drug Class and Drug Targeting 148
8.3 α-Adrenergic Receptor Antagonists 150
8.4 β-Adrenergic Receptor Antagonists 150
8.4.1 General Introduction to Drug Class 151
8.4.2 Chemistry and Pharmacokinetics 152
8.4.3 Molecular Mechanisms and Pharmacological Effects 152
8.4.4 Clinical Uses 155
8.4.5 Dosage Forms and Strengths 157
8.4.6 Adverse Effects and Drug Interactions 157
8.5 Centrally Acting Sympatholytics 157
8.6 Summary of Chapter Key Points 158
8.7 Self-Assessment Questions 159
References 159

9 Inhibitors of the Renin–Angiotensin–Aldosterone System 161
9.1 Overview 161
9.2 The RAAS and Drug Targeting 161
9.2.1 History for Discovery of RAAS and Development of the RAAS Inhibitors 161
9.2.2 The RAAS 162
9.2.3 Drug Class and Drug Targeting 162
9.3 Direct Renin Inhibitors 162
9.3.1 General Introduction to Drug Class 162
9.3.2 Chemistry and Pharmacokinetics 163
9.3.3 Molecular Mechanisms and Pharmacological Effects 164
9.3.4 Clinical Uses 165
9.3.5 Therapeutic Dosages 166
9.3.6 Adverse Effects and Drug Interactions 166
9.3.7 Summary of Aliskiren 166

9.4 ACE Inhibitors 166
9.4.1 General Introduction to Drug Class 167
9.4.2 Chemistry and Pharmacokinetics 167
9.4.3 Molecular Mechanisms and Pharmacological Effects 167
9.4.4 Clinical Uses 168
9.4.5 Therapeutic Dosages 170
9.4.6 Adverse Effects and Drug Interactions 171
9.4.7 Summary of ACE Inhibitors 174

9.5 ARBs 174
9.5.1 General Introduction to Drug Class 174
9.5.2 Chemistry and Pharmacokinetics 174
9.5.3 Molecular Mechanisms and Pharmacological Effects 174
9.5.4 Clinical Uses 176
9.5.5 Therapeutic Dosages 178
9.5.6 Adverse Effects and Drug Interactions 178
9.5.7 Summary of ARBs 178

9.6 Comparative Pharmacology of Direct Renin Inhibitors, ACE Inhibitors, and ARBs 179
9.6.1 Clinical Equivalence 179
9.6.2 Comparative Effectiveness Review 180
9.6.3 Future Research Needs 180

9.7 Summary of Chapter Key Points 181
9.8 Self-Assessment Questions 181
References 182

10 Calcium Channel Blockers 185
10.1 Overview 185
10.2 Calcium Channels and Drug Targeting 185
10.2.1 Calcium Channels 185
10.2.2 Drug Class and Drug Targeting 185

10.3 L-TYPE CCBs 186
10.3.1 General Introduction to Drug Class 186
10.3.2 Chemistry and Pharmacokinetics 186
10.3.3 Molecular Mechanisms and Pharmacological Effects 186
10.3.4 Clinical Uses 188
10.3.5 Therapeutic Dosages 190
10.3.6 Adverse Effects and Drug Interactions 190

10.4 Summary of Chapter Key Points 192
10.5 Self-Assessment Questions 192
References 193

11 Nitrates and Other Vasodilators 194
11.1 Overview 194
11.2 Drug Class and Drug Targeting 194
11.2.1 Molecular Regulation of Vascular Tone 194
11.2.2 Drug Class 196

11.3 Organic Nitrates and Sodium Nitroprusside (Nitric Oxide-Releasing Vasodilators) 196
11.3.1 General Introduction to Drug Class 196
11.3.2 Chemistry and Pharmacokinetics 196
11.3.3 Molecular Mechanisms and Pharmacological Effects 197
15 Management of Stable Angina/Stable Ischemic Heart Disease: Principles and Guidelines 262

15.1 Overview 262

15.2 Introduction to Current Guidelines on Management of Stable Angina/SIHD 262

15.2.1 Guidelines from the AHA and Its Collaborative Organizations 262
15.2.2 The ESC Guidelines 264
15.2.3 The 2011 NICE Guideline 265

15.3 General Principles of Management of Stable Angina/SIHD 265

15.3.1 Defining Treatment Objectives 265
15.3.2 Identifying Strategies to Attain the Treatment Objectives 266

15.4 Current Guideline Recommendations on Stable Angina/SIHD Management 266

15.4.1 Drug Therapy to Relieve Symptoms 266
15.4.2 Drug Therapy to Prevent Myocardial Infarction and Mortality 267
15.4.3 Revascularization 269

15.5 Management of Special Types of Stable Angina 271

15.5.1 Microvascular Angina 271
15.5.2 Vasospastic Angina 271
15.5.3 Refractory Stable Angina 272

15.6 Summary of Chapter Key Points 273

15.7 Self-Assessment Questions 273

References 273

UNIT V ISCHEMIC HEART DISEASE: ACUTE CORONARY SYNDROMES 275

16 Overview of Acute Coronary Syndromes and Drug Therapy 277

16.1 Introduction 277

16.2 Definitions and General Considerations 277

16.2.1 Definitions 277
16.2.2 Historical Overview 277
16.2.3 Global Burden 278

16.3 Pathophysiology and Drug Targeting 278

16.3.1 Historical Overview 278
16.3.2 Molecular Pathophysiology 278
16.3.3 Drug Targeting 279

16.4 Summary of Chapter Key Points 280

16.5 Self-Assessment Questions 281

References 281

17 Anticoagulants, Platelet Inhibitors, and Thrombolytic Agents 283

17.1 Overview 283

17.2 Hemostasis 283

17.2.1 Definitions 283
17.2.2 Physiology 283
17.2.3 Disorders of Hemostasis and Drug Therapy 285

17.3 Anticoagulants 285

17.3.1 Vitamin K Antagonists 285
17.3.2 Heparins 287
17.3.3 SFXa Inhibitors 290
17.3.4 Direct Thrombin (Factor IIa) Inhibitors 293
17.4 Platelet Inhibitors 295
   17.4.1 COX Inhibitors 296
   17.4.2 P2Y_{12} ADP-Receptor Antagonists 297
   17.4.3 Thrombin Receptor Antagonists 300
   17.4.4 Glycoprotein IIb/IIIa Antagonists 302
   17.4.5 Other Platelet Inhibitors 304
17.5 Thrombolytic Agents 304
   17.5.1 General Introduction to Drug Class 304
   17.5.2 Chemistry and Pharmacokinetics 305
   17.5.3 Molecular Mechanisms and Pharmacological Effects 306
   17.5.4 Clinical Uses 306
   17.5.5 Therapeutic Dosages 307
   17.5.6 Adverse Effects and Drug Interactions 307
17.6 Summary of Chapter Key Points 307
17.7 Self-Assessment Questions 307
References 308

18 Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction: Principles and Guidelines 310
18.1 Overview 310
18.2 Introduction to Evidence-Based Guidelines 310
   18.2.1 The ACC/AHA 2007 Guideline and Its Focused Updates in 2011 and 2012 310
   18.2.2 The ESC 2011 Guideline 311
   18.2.3 Major New Changes of the ACCF/AHA 2011/2012 Focused Updates and the ESC 2011 Guideline 311
   18.2.4 The NICE 2010 Guideline 311
   18.2.5 Other Guidelines 311
18.3 General Principles of Management of UA/NSTEMI 311
18.4 Guideline-Based Recommendations on the Management of UA/NSTEMI 311
   18.4.1 Anti-ischemic and Analgesic Therapy 312
   18.4.2 Antiplatelet Therapy 312
   18.4.3 Anticoagulant Therapy 312
   18.4.4 Additional Considerations on Antithrombotic (Antiplatelet and Anticoagulant) Therapy 312
   18.4.5 Coronary Revascularization 318
   18.4.6 Recommendations for Special Patient Groups 318
   18.4.7 Long-Term Management 323
18.5 Summary of Chapter Key Points 324
18.6 Self-Assessment Questions 325
References 325

19 Management of ST-Elevation Myocardial Infarction: Principles and Guidelines 327
19.1 Overview 327
19.2 Definition and Epidemiology 327
19.3 Introduction to Recent Guidelines on the Management of STEMI 328
   19.3.1 The ACCF/AHA Guidelines 328
   19.3.2 Other Guidelines 328
19.4 Principles and Guideline Recommendations for the Management of STEMI 329
   19.4.1 General Principles 329
   19.4.2 The 2013 ACCF/AHA Guideline Recommendations 330
19.5 Summary of Chapter Key Points 339
19.6 Self-Assessment Questions 340
References 340
UNIT VI HEART FAILURE 343

20 Overview of Heart Failure and Drug Therapy 345
  20.1 Introduction 345
  20.2 Definition, Classification, and Epidemiology 345
    20.2.1 Definition 345
    20.2.2 Classification 345
    20.2.3 Epidemiology 347
  20.3 Pathophysiology and Drug Targeting 348
    20.3.1 Pathophysiology of HF-REF and Drug Targeting 348
    20.3.2 Pathophysiology of HF-PEF and Drug Targeting 349
  20.4 Summary of Chapter Key Points 349
  20.5 Self-Assessment Questions 350
References 350

21 Drugs for Heart Failure 352
  21.1 Overview 352
  21.2 Diuretics for Heart Failure 352
  21.3 β-Blockers for HF 352
  21.4 Inhibitors of the RAAS for HF 353
    21.4.1 ACEIs 353
    21.4.2 ARBs 353
    21.4.3 Aldosterone Receptor Antagonists 353
    21.4.4 Direct Renin Inhibitors 354
  21.5 Vasodilators for HF 354
    21.5.1 Vasodilators in Acute HF 354
    21.5.2 Vasodilators in Chronic HF 354
  21.6 Positive Inotropic Agents for HF 354
    21.6.1 Introduction 355
    21.6.2 Digitalis (Digoxin) 355
    21.6.3 Dobutamine and Dopamine 357
    21.6.4 PDE3 Inhibitors 359
    21.6.5 Calcium-Sensitizing Agents 359
  21.7 Emerging Drugs for HF 359
  21.8 Summary of Chapter Key Points 360
  21.9 Self-Assessment Questions 360
References 361

22 Management of Heart Failure: Principles and Guidelines 364
  22.1 Overview 364
  22.2 Management of Hf-REF 364
    22.2.1 Introduction to Current Guidelines on the Management of HF-REF 364
    22.2.2 The 2013 ACCF/AHA Guideline Recommendations for Treatment of HF Stages A to D 365
  22.3 Management of HF-PEF 367
    22.3.1 General Considerations 367
    22.3.2 Guideline Recommendations 368
  22.4 Management of Acute Heart Failure Syndromes 368
    22.4.1 Definition and Precipitating Factors 368
    22.4.2 Principles of Management 369
    22.4.3 Guideline Recommendations 370
  22.5 Summary of Chapter Key Points 372
  22.6 Self-Assessment Questions 373
References 374
UNIT VII  CARDIAC ARRHYTHMIAS 375

23 Overview of Cardiac Arrhythmias and Drug Therapy 377
   23.1 Introduction 377
   23.2 Definition, Classification, and Epidemiology 377
      23.2.1 Definition and General Considerations 377
      23.2.2 The ICD-10 Classification 377
      23.2.3 Conventional Classification 378
      23.2.4 Epidemiology 378
   23.3 Pathophysiology and Drug Targeting 380
      23.3.1 Pathophysiology 380
      23.3.2 Drug Targeting 387
   23.4 Summary of Chapter Key Points 388
   23.5 Self-Assessment Questions 389
References 390

24 Drugs for Cardiac Arrhythmias 391
   24.1 Overview 391
   24.2 Classification of Antiarrhythmic Drugs 391
   24.3 Class I Antiarrhythmic Drugs 392
      24.3.1 General Aspects of Class I Drugs 392
      24.3.2 Specific Class IA Drugs 393
      24.3.3 Specific Class IB Drugs 394
      24.3.4 Specific Class IC Drugs 396
   24.4 Class II Antiarrhythmic Drugs 398
      24.4.1 General Aspects 398
      24.4.2 β-Blockers Commonly Used for Treating Arrhythmias 398
   24.5 Class III Antiarrhythmic Drugs 399
      24.5.1 General Aspects 399
      24.5.2 Specific Class III Drugs 399
   24.6 Class IV Antiarrhythmic Drugs 404
      24.6.1 General Aspects 404
      24.6.2 Chemistry and Pharmacokinetics 404
      24.6.3 Molecular Mechanisms and Pharmacological Effects 404
      24.6.4 Clinical Uses and Therapeutic Dosages 405
      24.6.5 Adverse Effects and Drug Interactions 406
   24.7 Other Antiarrhythmic Drugs 406
      24.7.1 Adenosine 406
      24.7.2 Magnesium 407
      24.7.3 Vernakalant 408
   24.8 Summary of Chapter Key Points 408
   24.9 Self-Assessment Questions 409
References 410

25 Management of Cardiac Arrhythmias: Principles and Guidelines 411
   25.1 Overview 411
   25.2 General Principles of Management 411
   25.3 Management of Supraventricular Arrhythmias 411
      25.3.1 Guidelines on Supraventricular Arrhythmias Excluding AF 412
      25.3.2 Current Guidelines on the Management of AF 412
   25.4 Management of Ventricular Arrhythmias 414
      25.4.1 General Considerations 414
25.4.2 General Principles of Management of Ventricular Arrhythmias 416
25.4.3 Guideline Recommendations for the Management of Ventricular Arrhythmias 420
25.5 Summary of Chapter Key Points 421
25.6 Self-Assessment Questions 423
References 424

UNIT VIII  ISCHEMIC STROKE  427

26 Overview of Ischemic Stroke and Drug Therapy  429
26.1 Introduction 429
26.2 Definition and Classification of Cerebrovascular Diseases 429
26.2.1 Definition of Cerebrovascular Diseases 429
26.2.2 The ICD-10 Classification of Cerebrovascular Diseases 429
26.3 Definition and Classification of Stroke 429
26.4 Epidemiology of Stroke 430
26.5 Risk Factors of Stroke 432
26.6 Pathophysiology of Ischemic Stroke and Drug Targeting 432
26.6.1 Pathophysiology of Ischemic Stroke 432
26.6.2 Drug Targeting in Ischemic Stroke 432
26.7 Summary of Chapter Key Points 434
26.8 Self-Assessment Questions 434
References 435

27 Drugs for Ischemic Stroke  436
27.1 Overview 436
27.2 Drugs for Primary Prevention of Ischemic Stroke 436
27.2.1 Treatment of Hypertension 436
27.2.2 Treatment of Dyslipidemias with Statins 437
27.2.3 Treatment of Comoribund Conditions of Diabetics: Antihypertensives and Statins 437
27.2.4 Treatment of AF with Anticoagulants and Antiplatelet Agents 437
27.3 Drugs for Early Treatment of Acute Ischemic Stroke 438
27.3.1 Thrombolytic Drugs 438
27.3.2 Antiplatelet Agents 439
27.3.3 Anticoagulants 439
27.4 Drugs for Neuroprotection 439
27.4.1 Definition of Neuroprotection 439
27.4.2 Edaravone 440
27.4.3 Citicoline 440
27.4.4 Statins 440
27.5 Drugs for Secondary Prevention of Ischemic Stroke 441
27.5.1 Drugs for General Risk Factor Reduction 441
27.5.2 Drugs for Patients with Cardiogenic Embolism 441
27.5.3 Antithrombotic Therapy for Noncardioembolic Stroke (Specifically Atherosclerotic, Lacunar, or Cryptogenic Infarcts) and TIA 442
27.6 Stem Cell Therapy for Neurorepair 442
27.7 Summary of Chapter Key Points 442
27.8 Self-Assessment Questions 443
References 444